- Home
- CSAI vs SGMT Comparison
CSAI vs SGMT Comparison
Compare CSAI & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSAI
- SGMT
- Stock Information
- Founded
- CSAI N/A
- SGMT 2006
- Country
- CSAI
- SGMT United States
- Employees
- CSAI N/A
- SGMT N/A
- Industry
- CSAI
- SGMT
- Sector
- CSAI
- SGMT
- Exchange
- CSAI NYSE
- SGMT Nasdaq
- Market Cap
- CSAI 188.2M
- SGMT 165.4M
- IPO Year
- CSAI N/A
- SGMT 2023
- Fundamental
- Price
- CSAI $10.66
- SGMT $4.12
- Analyst Decision
- CSAI
- SGMT Strong Buy
- Analyst Count
- CSAI 0
- SGMT 7
- Target Price
- CSAI N/A
- SGMT $25.71
- AVG Volume (30 Days)
- CSAI N/A
- SGMT 864.8K
- Earning Date
- CSAI N/A
- SGMT 03-24-2025
- Dividend Yield
- CSAI N/A
- SGMT N/A
- EPS Growth
- CSAI N/A
- SGMT N/A
- EPS
- CSAI N/A
- SGMT N/A
- Revenue
- CSAI N/A
- SGMT N/A
- Revenue This Year
- CSAI N/A
- SGMT N/A
- Revenue Next Year
- CSAI N/A
- SGMT N/A
- P/E Ratio
- CSAI N/A
- SGMT N/A
- Revenue Growth
- CSAI N/A
- SGMT N/A
- 52 Week Low
- CSAI N/A
- SGMT $2.39
- 52 Week High
- CSAI N/A
- SGMT $7.64
- Technical
- Relative Strength Index (RSI)
- CSAI N/A
- SGMT 43.11
- Support Level
- CSAI N/A
- SGMT $3.96
- Resistance Level
- CSAI N/A
- SGMT $4.83
- Average True Range (ATR)
- CSAI 0.00
- SGMT 0.38
- MACD
- CSAI 0.00
- SGMT -0.04
- Stochastic Oscillator
- CSAI 0.00
- SGMT 13.39
About CSAI CLOUDASTRUCTURE INC
Cloudastructure Inc is engaged in cloud-based artificial intelligence ("AI") video surveillance and Remote Guarding service built on AI and machine learning platforms. Its products/ services include Cloud Video Surveillance, Remote Guarding, Remote Guards, Cloud Video Recorder (CVR), Cameras and Speakers, Mobile Surveillance Trailer, etc.
About SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company focused on developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. The company's lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH).